北京基因型耐多药结核分枝杆菌二线抗结核药物耐药基因突变特征分析

doi:10.19485/j.cnki.issn2096-5087.2021.10.003

Preventive Medicine

2021, Vol. 33

Issue (10): 983-987 DOI: 10.19485/j.cnki.issn2096-5087.2021.10.003

Original Articles

Current Issue | Archive | Adv Search

Second-line drug resistance associated mutations in multidrug-resistant Mycobacterium tuberculosis Beijing genotype strains

YE Jingfen^*, FANG Qing, HU Yaoren, XU Xiaomin, CHE Yang

^*Department of Infection, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang 315010, China

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (849 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To learn the characteristics of second-line drug resistance and related gene mutations of multidrug-resistant Mycobacterium tuberculosis ( MDR-TB ) Beijing genotype strains. Methods The MDR-TB isolates in Hwa Mei Hospital from 2017 to 2019 were enrolled and detected using RD105 deletion-targeted multiplex polymerase chain reaction (PCR). The proportion method for drug susceptibility test was used to detect the drug-resistant profiles against kanamycin, amikacin, capreomycin, ofloxacin and levofloxacin. The gene sequencing of rrs, tlyA, eis, gidB, gyrA and gyrB was conducted by PCR compared with H₃₇RV strain. The differences in the rates of drug resistance and mutation between Beijing and non-Beijing genotype strains were examined to understand the characteristics of Beijing genotype strains. Results There were 106 Beijing genotype and 27 non-Beijing genotype strains in 133 MDR-TB isolates. The drug resistance rates of kanamycin, amikacin, capreomycin, ofloxacin and levofloxacin in Beijing genotype strains were 9.43%, 7.55%, 3.77%, 32.08% and 32.08%, respectively. The rates of quasi-extensive and extensive drug resistance in Beijing genotype strains were 30.19% and 7.55%. The gene mutation rates of rrs, tlyA, eis, gidB, gyrA and gyrB in Beijing genotype strains were 7.55%, 7.55%, 1.89%, 2.83%, 36.79% and 2.83%, respectively. There were no significantly differences between Beijing and Non-Beijing genotype strains in the factors above ( P>0.05 ). The gene rrs, tlyA, eis, gidB, gyrA and gyrB had 2, 1, 2, 2, 5 and 3 mutation types, respectively, with single base substitution as the main type. Conclusion Beijing genotype strains are dominant in MDR-TB, with high resistance to fluoroquinolones and mainly gyrA gene mutation.

Key words： Mycobacterium tuberculosis Beijing genotype drug resistance mutation

Received: 03 September 2021 Revised: 15 September 2021 Published: 30 September 2021

ZTFLH:

R521

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YE Jingfen
	FANG Qing
	HU Yaoren
	XU Xiaomin
	CHE Yang

Cite this article:

YE Jingfen,FANG Qing,HU Yaoren, et al. Second-line drug resistance associated mutations in multidrug-resistant Mycobacterium tuberculosis Beijing genotype strains[J]. Preventive Medicine, 2021, 33(10): 983-987.

URL:

http://www.zjyfyxzz.com/EN/10.19485/j.cnki.issn2096-5087.2021.10.003 OR http://www.zjyfyxzz.com/EN/Y2021/V33/I10/983

[1] World Health Organization.Global tuberculosis report 2019[R]. Geneva:World Health Organization,2019.
[2] ZUMLA A I,GILLESPIE S H,HOELSCHER M,et al.New antituberculosis drugs,regimens,and adjunct therapies:needs,advances,and future prospects[J].Lancet Infect Dis,2014,14(4):327-340.
[3] PARWATI I,VAN CREVEL R,VAN SOOLINGEN D.Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains[J].Lancet Infect Dis,2010,10(2):103-111.
[4] YANG C G,LUO T,SUN G M,et al.Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China[J].Clin Infect Dis,2012,55(9):1179-1187.
[5] YUAN X L,ZHANG T T,KAWAKAMI K,et al.Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China[J/OL].BMC Infect Dis(2013-07-12)[2021-09-15].https://link.springer.com/article/10.1186/1471-2334-13-315.
[6] CHEN Q Y,PANG Y,LIANG Q F,et al.Molecular characteristics of MDR Mycobacterium tuberculosis strains isolated in Fujian,China[J].Tuberculosis(Edinb),2014,94(2):159-161.
[7] KENDALL E A,COHEN T,MITNICK C D,et al.Second-line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis:a quantitative perspective[J].Int J Infect Dis,2017,56:185-189.
[8] SHARMA A K,GUPTA N,KALA D K,et al.A study on pattern of resistance to second-line anti tubercular drugs among multi drug resistant tuberculosis patients[J].Indian J Tuberc,2018,65(3):233-236.
[9] 中国防痨协会基础委员会.结核病诊断实验室检验规程[M]. 北京:中国教育文化出版社,2006:49-51.
[10] ABDEL A M,ABIGAIL W.The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance:a model for other infectious diseases[J]. Clin Infect Dis,2005,41(Suppl. 4):S258-S262.
[11] 中国防痨协会.耐药结核病化学治疗指南(2019年简版)[J].中国防痨杂志,2019,41(10):1026-1027.
[12] CHEN J,TSOLAKI A G,SHEN X,et al.Deletion-targeted multiplex PCR(DTM-PCR)for identification of Beijing/W genotypes of Mycobacterium tuberculosis[J].Tuberculosis,2007,87(5):446-449.
[13] 刘海灿,赵丽丽,赵秀芹,等. 耐多药结核分枝杆菌二线药物耐药相关基因分析[J].疾病监测,2016,31(6):471-476.
[14] 郭海萍,尚媛媛. 全基因组测序在结核病分子流行病学研究中的应用[J]. 预防医学,2020,32(9):899-903.
[15] 纪律,刘晓俊,余云芳,等. 宜昌市耐药结核分枝杆菌MIRU-VNTR分子特征及耐药基因突变分析[J]. 预防医学,2021,33(2):149-152.
[16] YUAN X,ZHANG T,KAWAKAMI K,et al.Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China[J].BMC Infect Dis,2013,13(2):315-318.
[17] OKAMOTO S,TAMARU A,NAKAJIMA C,et al.Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria[J].Mol Microbiol,2007,63(4):1096-1106.
[18] ZHANG Z,LU J,WANG Y,et al.Prevalence and molecular characterization of fluoroquinolone Mycobacterium tuberculosis isolates in China[J].Antimicrob Agents Chemother,2014,58(1):364-369.